Overview

A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor

Status:
Completed

Trial end date:
2020-11-05

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study will also evaluate the safety of ASP0113 in this patient population.

Phase:

Phase 2

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Collaborator:

Vical